Patents by Inventor Martha Jo Whitehouse
Martha Jo Whitehouse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170151311Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: ApplicationFiled: January 23, 2017Publication date: June 1, 2017Inventors: Elaine Unemori, Sam L Teichman, Gad Cotter, Dennis Stewart, Martha Jo Whitehouse
-
Patent number: 9579363Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: GrantFiled: May 28, 2015Date of Patent: February 28, 2017Assignee: Corthera Inc.Inventors: Elaine Unemori, Sam L Teichman, Gad Cotter, Dennis Stewart, Martha Jo Whitehouse
-
Publication number: 20160287672Abstract: The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin.Type: ApplicationFiled: April 25, 2016Publication date: October 6, 2016Inventors: Elaine Unemori, Sam Teichman, Thomas Dschietzig, Dennis R. Stewart, Martha Jo Whitehouse
-
Patent number: 9205132Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: GrantFiled: March 5, 2013Date of Patent: December 8, 2015Assignee: CORTHERA, INC.Inventors: Elaine Unemori, Sam L. Teichman, Gad Cotter, Dennis Stewart, Martha Jo Whitehouse
-
Publication number: 20150320834Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: ApplicationFiled: May 28, 2015Publication date: November 12, 2015Inventors: Elaine Unemori, Sam L. Teichman, Gad Cotter, Dennis Stewart, Martha Jo Whitehouse
-
Patent number: 9066916Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: GrantFiled: January 4, 2013Date of Patent: June 30, 2015Assignee: CORTHERA, INC.Inventors: Elaine Unemori, Sam Teichman, Gad Cotter, Dennis Stewart, Martha Jo Whitehouse
-
Publication number: 20140349932Abstract: The present invention provides a unit dose composition comprising 0.2 ?g/kg to 48 ?g/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.Type: ApplicationFiled: June 23, 2014Publication date: November 27, 2014Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventor: Martha Jo Whitehouse
-
Patent number: 8796211Abstract: The present invention provides a unit dose composition comprising 0.2 ?g/kg to 48 ?g/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.Type: GrantFiled: April 15, 2011Date of Patent: August 5, 2014Assignee: Novartis Vaccines and Diagnostics, Inc.Inventor: Martha Jo Whitehouse
-
Publication number: 20140005112Abstract: The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin.Type: ApplicationFiled: July 11, 2013Publication date: January 2, 2014Inventors: Elaine Unemori, Sam Teichman, Thomas Dschietzig, Dennis R. Stewart, Martha Jo Whitehouse
-
Publication number: 20130210730Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: ApplicationFiled: March 5, 2013Publication date: August 15, 2013Applicant: NOVARTIS AGInventors: Elaine Unemori, Sam L. Teichman, Gad Cotter, Dennis Stewart, Martha Jo Whitehouse
-
Publication number: 20120289464Abstract: The present invention provides a unit dose composition comprising 0.2 ?g/kg to 48 ?g/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.Type: ApplicationFiled: April 15, 2011Publication date: November 15, 2012Applicant: Novartis Vaccines and Diagnostics, Inc.Inventor: Martha Jo Whitehouse
-
Publication number: 20120040902Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: ApplicationFiled: September 23, 2011Publication date: February 16, 2012Inventors: Elaine Unemori, Sam L. Teichman, Gad Cotter, Dennis R. Stewart, Martha Jo Whitehouse
-
Patent number: 8053411Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: GrantFiled: May 15, 2009Date of Patent: November 8, 2011Assignee: Corthera, Inc.Inventors: Elaine Unemori, Sam L. Teichman, Gad Cotter, Dennis R. Stewart, Martha Jo Whitehouse
-
Publication number: 20100048475Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: ApplicationFiled: May 15, 2009Publication date: February 25, 2010Applicant: Corthera, Inc.Inventors: Elaine Unemori, Sam L. Teichman, Gad Cotter, Dennis R. Stewart, Martha Jo Whitehouse
-
Patent number: 7541333Abstract: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 ?g/kg to 48 ?g/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts 2 months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety.Type: GrantFiled: August 28, 2006Date of Patent: June 2, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventor: Martha Jo Whitehouse
-
Patent number: 7541337Abstract: Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective amount of FGF-2 and a pharmaceutically acceptable carrier are also provided. The methods of the invention to treat peripheral artery disease and claudication comprise administering at least a single dose of a pharmaceutical composition comprising the FGF, such as FGF-2, via intra-arterial, intravenous, or intramuscular infusion to the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.Type: GrantFiled: February 5, 2007Date of Patent: June 2, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventor: Martha Jo Whitehouse
-
Publication number: 20080242648Abstract: The present embodiments relate to compositions and methods of treatment of cancer. More particularly, the present embodiments relate to the combination of an ER?+ ligand with an HDACi for the treatment of cancer, methods of treating cancer and pharmaceutical compositions for treating cancer.Type: ApplicationFiled: November 9, 2007Publication date: October 2, 2008Applicant: Syndax Pharmaceuticals, Inc., a California CorporationInventors: Peter Ordentlich, Joanna Horobin, Martha Jo Whitehouse, Miranda Rees
-
Patent number: 7186407Abstract: Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective amount of FGF-2 and a pharmaceutically acceptable carrier are also provided. The methods of the invention to treat peripheral artery disease and claudication comprise administering at least a single dose of a pharmaceutical composition comprising the FGF, such as FGF-2, via intra-arterial, intravenous, or intramuscular infusion to the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.Type: GrantFiled: May 14, 2004Date of Patent: March 6, 2007Assignee: Chiron CorporationInventor: Martha Jo Whitehouse
-
Publication number: 20040209817Abstract: Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective amount of FGF-2 and a pharmaceutically acceptable carrier are also provided. The methods of the invention to treat peripheral artery disease and claudication comprise administering at least a single dose of a pharmaceutical composition comprising the FGF, such as FGF-2, via intra-arterial, intravenous, or intramuscular infusion to the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.Type: ApplicationFiled: May 14, 2004Publication date: October 21, 2004Applicant: Chiron CorporationInventor: Martha Jo Whitehouse
-
Publication number: 20030166550Abstract: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 &mgr;g/kg to 48 &mgr;g/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts six months before retreatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety.Type: ApplicationFiled: June 28, 2002Publication date: September 4, 2003Applicant: Chiron CorporationInventor: Martha Jo Whitehouse